Slides
Page 1
COLOR PALETTE 0 Q1FY27 Results July 2026
Page 2
COLOR PALETTE 1 This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner, or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities of the Company in any jurisdiction, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. Except for the historical information contained herein, statements in this Presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continue', 'anticipate', 'estimate', 'intend', 'plan', 'contemplate', 'seek to', 'future', 'objective', 'goal', 'likely', 'project', 'on-course', 'should', 'potential', 'pipeline', 'guidance', 'will pursue' 'trend line' and similar expressions or variations of such expressions may constitute 'forward-looking statements'. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to Company’s ability to successfully implement its strategy, the Company’s growth and expansion plans, the performance of the Indian economy and of the economies of various international markets, obtain regulatory approvals, provisioning policies, technological changes, investment and business income, income or cash flow projections, the performance of the industry in India and world-wide, exposure to market risks as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially from results expressed in or implied by this Presentation. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. Given these uncertainties and other factors, viewers of this Presentation are cautioned not to place undue reliance on these forward-looking statements. The information in this Presentation does not constitute financial advice (nor investment, tax, accounting or legal advice) and does not take into account an investor’s individual investment objectives, including the merits and risks involved in an investment in the Company or its securities, or an investor’s financial situation, tax position or particular needs. Past performance information in this Presentation should not be relied upon as an indication of (and is not an indicator of) future performance. This Presentation is not a prospectus, disclosure document, a statement in lieu of a prospectus, an offering circular, an invitation or an advertisement or an offer document under the Companies Act, 2013, together with the rules and regulations made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation, and nothing in this Presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. The Presentation has not been independently verified and any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. The contents of this Presentation are strictly confidential and may not be copied or disseminated, reproduced, re-circulated, published, advertised or redistributed, in whole or in part, to any other person or in any media, website or otherwise in any manner without the Company’s written consent. Note: Figures in previous periods might have been regrouped or restated, wherever necessary to make them comparable to current period. For the ease of presentation, certain financial information herein has been rounded off to one decimal place or two decimal places or whole numbers, as the case may be. Disclaimer
Page 3
COLOR PALETTE 2 Performance Highlights
Page 4
COLOR PALETTE A Positive Start to FY2027: Momentum Across All Three Businesses 3 “ We have started FY2027 on a strong note. As guided, all the three businesses delivered healthy revenue growth with improvement in EBITDA margins. 01 CDMO Broad-based performance across India and overseas sites; Focus on strong execution Favorable industry trends, diversified customer demand, enhanced commercial team and strong execution across the network position us well for sustained growth and margin improvement. 02 CHG Pick-up in ex-US inhalation anesthesia sales; Kenalog supplies to start from Q2FY27 Delivered a resilient Q1, sustaining leadership in core therapies, expanding ex-US traction, progressing Kenalog integration and differentiated pipeline initiatives, while maintaining cost discipline amid supply and input-cost headwinds. 03 PCH Power brands and e-commerce continue to outperform Delivered strong mid-teen growth, driven by Power Brands, e-commerce expansion and disciplined brand investments. Supported by premiumization, wider distribution and profitability initiatives, the business remains well positioned for sustainable, profitable growth. W e e x p e c t t o b u i l d o n t h i s s t r o n g s t a r t t h r o u g h t h e r e m a i n d e r o f F Y 2 7 , d e l i v e r i n g r o b u s t r e v e n u e g r o w t h a n d s i g n i f i c a n t e x p a n s i o n i n p r o f i t a b i l i t y . Nandini Piramal C H A I R P E R S O N
Page 5
COLOR PALETTE Q1FY27 Financial Performance: Broad-Based Growth & Margin Expansion EBITDARevenue from Operations (In ₹ Crore) 1,934 2,270 Q1FY26 Q1FY27 165 285 Q1FY26 Q1FY27 (In ₹ Crore) 4 17 % 72 % EBITDA Margin 8.5% 12.5% Q1FY26 Q1FY27 CHGCDMO (In ₹ Crore) 997 1,187 Q1FY26 Q1FY27 637 743 Q1FY26 Q1FY27 (In ₹ Crore) 19 % 17 % PCH 302 347 Q1FY26 Q1FY27 15 % (In ₹ Crore) 400 bps
Page 6
COLOR PALETTE 997 1,187 Q1FY26 Q1FY27 Strong start to the year with 19% YoY revenue growth driven by: ❖ Healthy pick-up in RFPs and order inflows across multiple sites supported by enhanced commercial team and improved win rates • Significant surge in RFP activity in the last few quarters, however, customer decision-making timelines remains prolonged. Maintaining our win rates and conversion of these RFPs into orders will be the key driver of growth. • Healthy demand for differentiated capabilities and innovation related work. ❖ Favorable external factors – Biopharma funding and supply-chain diversification • Biopharma funding in H1CY26 up over 100% vs H1CY25. (Industry reports) • Geopolitical & trade uncertainties are accelerating supply-chain diversification, driving demand for reliable multi-site CDMO partners. ❖ Superior execution with improved profitability across India and overseas sites • Margin expansion across most sites driven by improved utilization, pricing discipline and operational excellence, despite inflationary pressures. • Enhanced customer satisfaction scores underscore strong operational execution. • Maintained best-in-class quality track record with Zero OAI till date. (In ₹ Crore) CDMO Business: Return to Growth 5 Key Highlights Revenue Performance 19 %
Page 7
COLOR PALETTE Advancing our ADC Platform: Capacity, Capability & Partnerships 6 Building on our integrated ADCelerate platform — 20+ years in ADCs ON TRACK Lexington, US Scaling sterile injectables capacity • Key additions - Filling line, commercial lyophilizers, capping machine, external vial washer • Strengthens sterile fill-finish — the final step of the integrated ADC platform • Part of the US$90M expansion; seeing strong customer interest COMPLETED Riverview, US Commercial manufacturing capability • Commercial-scale payload-linker development & manufacturing • Advanced containment, automation & analytics for seamless scale-up • Dedicated payload-linker supply feeding ADCelerate PARTNERSHIP Ajinomoto Bio-Pharma Access to next-gen conjugation technology • Site-specific conjugation for homogeneous, higher-quality ADCs • Works on native antibodies — no antibody re-engineering • Two-way referral + technology transfer (Master Technology Agreement)
Page 8
COLOR PALETTE 637 743 Q1FY26 Q1FY27 7 ❖ Inhalation Anesthesia – Sustaining US Leadership; Building Ex-US Traction • US – Maintained leadership in Sevoflurane, #1 Rank with 48% value share. • Ex-US Markets – Healthy pickup across select markets, supported by strong ROW Sevoflurane performance. ❖ Intrathecal Therapy – Continued US Market Leadership • Maintained #1 Rank in intrathecal Baclofen in the US, reinforcing our strength in differentiated hospital therapies. ❖ Injectable Pain Management – Focused Actions to Improve Supply • Collaborating with suppliers to enhance product availability. ❖ Kenalog Integration – Supplies to Start from Q2FY27 • Progressing on integration activities. Supplies to start from Q2FY27. ❖ Building Portfolio of Differentiated and Specialty Products • Continued investment in 505(b)(2), complex / differentiated generics, branded products, in-licensing and co-development to strengthen long-term growth. Key Highlights Revenue Performance Complex Hospital Generics Business: Building Traction (In ₹ Crore) 7 17 % Note: Source for all market share data: IQVIA.
Page 9
COLOR PALETTE Consumer Healthcare Business: Sustaining Growth Momentum 8 Key Highlights Revenue Performance (In ₹ Crore) ❖ Delivered robust growth of 15% in Q1FY27 driven by: • Power Brands - Delivered 23% YoY growth, contributing 53% of PCH sales. • E-commerce - Delivered 40% YoY growth, contributing 28% of PCH sales. ❖ New Product Launches – Fewer – Bigger – Better • Focused on fewer,high-potential product launches with stronger success rates. • Premiumization of the portfolio with emphasis on higher-margin products. ❖ Continuous Investments in Media & Trade Promotion • Invested ~12% of PCH sales in media and trade promotion across digital and traditional channels - Social Media, Television,Influencers, etc. ❖ Expand Multi-channel Distribution Network • Presence across 180,000+ chemists & cosmetic shops, 13,000+ modern trade outlets, and 20+ e-commerce platforms. • Expanding reach in smaller towns, modern trade, and non-chemist channels. ❖ Focused on Profitability Improvement Amid a Challenging Cost Environment • Judicious price increase and cost optimization initiatives offset raw material inflation. 302 347 Q1FY26 Q1FY27 15 %
Page 10
COLOR PALETTE 131 125 148 FY24 FY25 FY26 Page 9 Focus on Power Brands with Brand Promotion and Marketing 9 % of PCH sales (In ₹ Cr) Investments in Brand Promotion and Marketing 13% 11% 12% 448 538 664 FY24 FY25 FY26 Strong Growth in our Power Brands 22% CAGR (In ₹ Cr) 38 41 Q1FY26 Q1FY27 149 184 Q1FY26 Q1FY27 13% 12% 23%
Page 11
COLOR PALETTE AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL 10 FY2026 PERFORMANCE ₹526 Cr. Revenue 23% PAT Margin Strong profitability and established market position MARKET POSITION One of the market leaders in the Indian ophthalmology segment INTEGRATED SOLUTIONS PPL CDMO business supplies ophthalmology products to the JV MARKET LEADING BRANDS Pred Forte Eye Inflammation Lumigan Glaucoma Combigan Glaucoma Refresh Tears Dry Eyes Alphagan Glaucoma Ownership 49% Ownership 51% LEADING MARKET POSITION INTEGRATED SOLUTIONS
Page 12
COLOR PALETTE 11 Financials
Page 13
COLOR PALETTE 12 (in ₹ Cr. or as stated) Particulars Q1FY27 Q1FY26 % Change Revenue from Operations1 2,270 1,934 17% CDMO 1,187 997 19% CHG 743 637 17% PCH 347 302 15% EBITDA 285 165 72% EBITDA Margin 12.5% 8.5% PAT (before exceptional item) (69) (102) 32% Exceptional Item - 21 NM PAT (after exceptional item) (69) (82) 15% 1. Revenue from Operations includes foreign exchange gains/losses Consolidated Financials Highlights Healthy Growth Across Businesses with EBITDA Margin Expansion
Page 14
COLOR PALETTE 13 Event Location & Time Telephone Number Conference call on 30th July 2026 India – 09:30 AM IST +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) 1 800 120 1221 (Toll free number) USA – 12:00 AM (Eastern Time – New York) Toll free number 18667462133 UK – 05:00 AM (London Time) Toll free number 08081011573 Singapore – 12:00 PM (Singapore Time) Toll free number 8001012045 Hong Kong – 12:00 PM (Hong Kong Time) Toll free number 800964448 Express Join with Diamond Pass Please use this link for prior registration to reduce wait time at the time of joining the call –Click here Dial-in Details for Q1FY27 Earnings Conference Call
Page 15
For Investor Queries: Madhusudan Dalmia Investor Relations Email: madhusudan.dalmia@piramal.com Gagan Borana Investor Relations and Enterprise Risk Management Email: gagan.borana@piramal.com Our Websites:- Piramal Pharma Limited www.piramalpharma.com Complex Hospital Generics www.piramalcriticalcare.com CDMO www.piramalpharmasolutions.com